Real information! http://www.marketwired.com/A
Post# of 72440
http://www.marketwired.com/AdvancedSearch/Adv...96c8479530
Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article
BEVERLY, MA --(Marketwired - December 17, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provi...
12/17/2015 11:15:58 AM
Cellceutix First Annual Shareholder Meeting December 15, 2015
BEVERLY, MA --(Marketwired - December 14, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today remin...
12/14/2015 7:30:00 AM
Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin and Skin Structure Infections
BEVERLY, MA --(Marketwired - December 11, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to in...
12/11/2015 9:18:34 AM
Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
BEVERLY, MA --(Marketwired - December 01, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an...
12/1/2015 10:31:56 AM
Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
BEVERLY, MA --(Marketwired - November 30, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced today...
11/30/2015 7:30:00 AM
FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
BEVERLY, MA --(Marketwired - November 25, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an...
11/25/2015 8:00:00 AM
Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
BEVERLY, MA --(Marketwired - November 23, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an...
11/23/2015 7:30:00 AM
Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer
BEVERLY, MA --(Marketwired - November 16, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports th...
11/16/2015 7:30:00 AM
Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics
BEVERLY, MA --(Marketwired - November 11, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to re...
11/11/2015 10:34:21 AM
Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015
BEVERLY, MA --(Marketwired - November 10, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its qu...
11/10/2015 10:51:02 AM